Dr. Gomella Discusses the PSA Screening Debate in 2013

Leonard G. Gomella, MD
Published: Friday, May 31, 2013



Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

The PSA screening debate has been beneficial, Gomella says, because it forces oncologists to go back, justify, and dissect the best way to screen patients for prostate cancer. It is recognized that not every patient needs to be screen but the challenge lies in identifying those who do and those who will benefit the most from PSA-based screening.

The combination of screening and understanding prostate cancer treatment must be considered together.
 


Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

The PSA screening debate has been beneficial, Gomella says, because it forces oncologists to go back, justify, and dissect the best way to screen patients for prostate cancer. It is recognized that not every patient needs to be screen but the challenge lies in identifying those who do and those who will benefit the most from PSA-based screening.

The combination of screening and understanding prostate cancer treatment must be considered together.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x